JIN-A02: 4th Gen EGFR TKI Phase 1/2 Study for NSCLC Accepted at AACR 2024

J INTS BIO has announced that the Phase 1/2 clinical trial of its new oral 4th generation EGFR TKI, named "JIN-A02," for treating non-small cell lung cancer (NSCLC) has been accepted for a poster presentation at the American Association for Cancer Research (AACR) meeting, which will take place in San Diego, USA, from April 5 to 10, 2024. AACR is a highly reputable cancer organization, considered one of the top three in the world, alongside the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). J INTS BIO will present their findings in a session on April 8, focusing on "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for patients resistant to 3rd generation EGFR-TKIs in advanced/metastatic NSCLC with EGFR mutations."

"JIN-A02" specifically targets the C797S mutation, which causes resistance to 3rd generation EGFR-TKIs like Osimertinib and Lazertinib in EGFR-positive NSCLC. The drug shows high selectivity and strong inhibition of NSCLC with C797S double or triple mutations and is expected to be effective against brain tumors due to its ability to cross the blood-brain barrier.

In August of the previous year, J INTS BIO began the global Phase 1/2 clinical trial of "JIN-A02" at Severance Hospital in Korea. The study is currently enrolling patients with EGFR mutation-positive advanced NSCLC at multiple locations in Korea and at the University of California, Irvine. The dose escalation phase has reached its 4th dosage level, and early effectiveness has been observed, especially in patients with the C797S mutation. J INTS BIO intends to increase the number of trial sites internationally and in Korea, including Seoul National University Hospital, Samsung Seoul Hospital, and Seoul St. Mary's Hospital.

A representative from J INTS BIO stated that the global clinical trial for "JIN-A02" is progressing well and attracting international interest. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!